Patients with active Rheumatoid Arthritis and an inadequate response to 1 or more non biologic DMARDS were randomized to receive intravenous Rituximab ( 1 course consisting of 2 infusions of 1.000 mg each - one group , and Etanercept 25 mg twice weekly - second group , but both groups with background MTX .